PMID- 33887491
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1522-9629 (Electronic)
IS  - 1094-5539 (Linking)
VI  - 68
DP  - 2021 Jun
TI  - Gentiopicroside ameliorates ovalbumin-induced airway inflammation in a mouse 
      model of allergic asthma via regulating SIRT1/NF-kappaB signaling pathway.
PG  - 102034
LID - S1094-5539(21)00046-8 [pii]
LID - 10.1016/j.pupt.2021.102034 [doi]
AB  - Allergic asthma is a common airway inflammatory disorder with increasing 
      morbidity and mortality worldwide. Gentiopicroside (GPS) is a secoiridoid 
      glycoside compound that exhibits anti-inflammatory property. However, the effect 
      of GPS on allergic asthma has not been reported yet. In this study, we 
      investigated the role of GPS in a mouse model of ovalbumin (OVA)-induced allergic 
      asthma and explored its potential mechanism. Mice were sensitized with OVA and 
      gavaged with 20, 40, or 80 mg/kg GPS. Administration of GPS decreased lung 
      wet-to-dry weight ratio. Histological analysis of H&E and PAS staining showed 
      that GPS treatment alleviated inflammatory cell infiltration and goblet cell 
      hyperplasia in lung tissue of OVA-sensitized mice. Moreover, GPS inhibited the 
      recruitment of inflammatory cells including total cells, macrophages, 
      eosinophils, lymphocytes and neutrophils and the secretion of T helper type 2 
      (Th2) cytokines (interleukin (IL)-4, IL-5 and IL-13) in bronchoalveolar lavage 
      fluid (BALF) of OVA-sensitized mice in a dose dependent manner. The levels of 
      OVA-specific immunoglobulin E (IgE) and pro-inflammatory tumor necrosis factor 
      (TNF)-alpha were also attenuated by GPS treatment. Interestingly, GPS upregulated the 
      expression of silent information regulator 1 (SIRT1) while downregulated the 
      expression of acetyl-nuclear factor kappa B (NF-kappaB) p65 in lung tissue of 
      OVA-sensitized mice. Furthermore, treatment with an SIRT1 inhibitor (EX-527) 
      partially abolished the inhibitory effect of GPS on OVA-induced airway 
      inflammation, suggesting that the anti-inflammation of GPS might be achieved 
      through regulating SIRT1/NF-kappaB p65 signaling pathway. These findings indicate 
      that GPS might be a novel drug candidate in the treatment of allergic asthma.
CI  - Copyright (c) 2021 Elsevier Ltd. All rights reserved.
FAU - Zou, Bo
AU  - Zou B
AD  - Institute of Respiratory Diseases, The First Hospital of China Medical 
      University, Shenyang City, Liaoning Province, People's Republic of China; 
      Department of Respiratory and Critical Care Medicine, The Fourth Affiliated 
      Hospital of China Medical University, Shenyang City, Liaoning Province, People's 
      Republic of China.
FAU - Fu, Yue
AU  - Fu Y
AD  - Institute of Respiratory Diseases, The First Hospital of China Medical 
      University, Shenyang City, Liaoning Province, People's Republic of China.
FAU - Cao, Chaofan
AU  - Cao C
AD  - Institute of Respiratory Diseases, The First Hospital of China Medical 
      University, Shenyang City, Liaoning Province, People's Republic of China; 
      Department of Respiratory Medicine, The Second Affiliated Hospital of Shenyang 
      Medical College, Shenyang City, Liaoning Province, People's Republic of China.
FAU - Pan, Dianzhu
AU  - Pan D
AD  - Department of Respiratory Medicine, The First Affiliated Hospital of Jinzhou 
      Medical University, Jinzhou City, Liaoning Province, People's Republic of China.
FAU - Wang, Wei
AU  - Wang W
AD  - Institute of Respiratory Diseases, The First Hospital of China Medical 
      University, Shenyang City, Liaoning Province, People's Republic of China.
FAU - Kong, Lingfei
AU  - Kong L
AD  - Institute of Respiratory Diseases, The First Hospital of China Medical 
      University, Shenyang City, Liaoning Province, People's Republic of China. 
      Electronic address: cmukonglf@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210419
PL  - England
TA  - Pulm Pharmacol Ther
JT  - Pulmonary pharmacology & therapeutics
JID - 9715279
RN  - 0 (Cytokines)
RN  - 0 (Iridoid Glucosides)
RN  - 0 (NF-kappa B)
RN  - 0WE09Z21RC (gentiopicroside)
RN  - 9006-59-1 (Ovalbumin)
RN  - EC 3.5.1.- (Sirt1 protein, mouse)
RN  - EC 3.5.1.- (Sirtuin 1)
SB  - IM
MH  - Animals
MH  - *Asthma/drug therapy
MH  - Bronchoalveolar Lavage Fluid
MH  - Cytokines
MH  - Disease Models, Animal
MH  - Inflammation/drug therapy
MH  - Iridoid Glucosides
MH  - Lung/metabolism
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - *NF-kappa B/metabolism
MH  - Ovalbumin
MH  - Signal Transduction
MH  - Sirtuin 1
OTO - NOTNLM
OT  - Airway inflammation
OT  - Allergic asthma
OT  - Gentiopicroside
OT  - NF-kappaB
OT  - SIRT1
EDAT- 2021/04/23 06:00
MHDA- 2021/09/30 06:00
CRDT- 2021/04/22 20:16
PHST- 2021/01/14 00:00 [received]
PHST- 2021/04/09 00:00 [revised]
PHST- 2021/04/15 00:00 [accepted]
PHST- 2021/04/23 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2021/04/22 20:16 [entrez]
AID - S1094-5539(21)00046-8 [pii]
AID - 10.1016/j.pupt.2021.102034 [doi]
PST - ppublish
SO  - Pulm Pharmacol Ther. 2021 Jun;68:102034. doi: 10.1016/j.pupt.2021.102034. Epub 
      2021 Apr 19.